DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?

Smelcerovic, Andrija; Kocic, Gordana; Gajic, Mihajlo; Tomovic, Katarina; Djordjevic, Vukica; Stankovic-Djordjevic, Dobrila; Anderluh, Marko

Smelcerovic, Andrija; Kocic, Gordana; Gajic, Mihajlo; Tomovic, Katarina; Djordjevic, Vukica; Stankovic-Djordjevic, Dobrila; Anderluh, Marko.

Afiliación

Smelcerovic A; Department of Chemistry, Faculty of Medicine, University of Nis, Nis, Serbia.
Kocic G; Department of Biochemistry, Faculty of Medicine, University of Nis, Nis, Serbia.
Gajic M; Department of Pharmacy, Faculty of Medicine, University of Nis, Nis, Serbia.
Tomovic K; Department of Pharmacy, Faculty of Medicine, University of Nis, Nis, Serbia.
Djordjevic V; Department of Microbiology and Immunology, Faculty of Medicine, University of Nis, Nis, Serbia.
Stankovic-Djordjevic D; Department of Microbiology and Immunology, Faculty of Medicine, University of Nis, Nis, Serbia.
Anderluh M; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

Front Pharmacol ; 11: 1185, 2020.

Article en En | MEDLINE | ID: mdl-32848788

Palabras clave

COVID-19; DPP-4 inhibitors; diabetes; fibrosis; multi-organ injury

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2020 Tipo del documento: Article Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google